SPAC Proposes Highly Dilutive $5.57B Merger with Preclinical Biotech SL Bio; Public Shareholders Face Extreme Dilution

summarizeSummary

The proposed de-SPAC merger between Horizon Space Acquisition II Corp. (HSPT) and SL Bio is a highly significant and negative event for HSPT's public shareholders. The transaction values SL Bio, a preclinical-stage biotech company with no FDA-approved products, at an exceptionally high $5.568 billion. This valuation, based on projections that are "inherently subject to significant uncertainty," leads to severe dilution for existing HSPT public shareholders, who will hold a minimal stake (1.34% to 0.17%) in the combined entity, PubCo. The pro forma equity value of PubCo is projected to be lower than HSPT's current market capitalization, indicating a substantial loss of value for HSPT shareholders. Furthermore, the transaction carries numerous risks, including SL Bio's heavy reliance on license agreements with entities where its CEO and CTO have significant ownership, the uncertainty of securing additional financing, and the less stringent corporate governance standards associated with PubCo's "controlled company" and "foreign private issuer" status. Investors should be aware of the substantial risks and potential for value destruction inherent in this highly dilutive and speculative business combination.

check_boxKey Events

• Business Combination Agreement

  Horizon Space Acquisition II Corp. (HSPT) is proposing a de-SPAC merger with SL BIO Ltd. (SL Bio), where both will become subsidiaries of a new public company, SL Science Holding Limited (PubCo). SL Bio is valued at $5.568 billion in the transaction.

• Extreme Shareholder Dilution

  HSPT public shareholders will experience significant dilution, with their ownership in PubCo ranging from 1.34% (assuming no redemptions) to 0.17% (assuming maximum redemptions).

• High Valuation for Preclinical Biotech

  SL Bio, a biomedical company with product candidates in preclinical trials and no FDA approvals, is being valued at $5.568 billion. The fairness opinion relies on financial projections that are inherently uncertain.

• Limited Liquidity Post-Merger

  The pro forma combined liquidity of PubCo is projected to be between $77.6 million (no redemptions) and $9.5 million (maximum redemptions), which is less than HSPT's current market capitalization in the best-case scenario.

auto_awesomeAnalysis

The proposed de-SPAC merger between Horizon Space Acquisition II Corp. (HSPT) and SL Bio is a highly significant and negative event for HSPT's public shareholders. The transaction values SL Bio, a preclinical-stage biotech company with no FDA-approved products, at an exceptionally high $5.568 billion. This valuation, based on projections that are "inherently subject to significant uncertainty," leads to severe dilution for existing HSPT public shareholders, who will hold a minimal stake (1.34% to 0.17%) in the combined entity, PubCo. The pro forma equity value of PubCo is projected to be lower than HSPT's current market capitalization, indicating a substantial loss of value for HSPT shareholders. Furthermore, the transaction carries numerous risks, including SL Bio's heavy reliance on license agreements with entities where its CEO and CTO have significant ownership, the uncertainty of securing additional financing, and the less stringent corporate governance standards associated with PubCo's "controlled company" and "foreign private issuer" status. Investors should be aware of the substantial risks and potential for value destruction inherent in this highly dilutive and speculative business combination.